Have questions about FDA 1572s?
FDA has updated its guidance documents for 1572s.
Don't worry, if the FDA 1572 seems confusing, you are not alone. In fact, the FDA updated its Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs--Frequently Asked Questions Statement of Investigator (Form FDA 1572)
The document was posted in July 2008, but according to an Applied Clinical Trials Editorial Advisory Board member believes with the myriad of
activities that clinical operations staff are responsible for some seem to have "missed" this update.
Also, a previous Applied Clinical Trials article on the subject could provide more help.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
